Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DKP0T7
|
|||
Drug Name |
GB001
|
|||
Drug Type |
Small molecule
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
Company |
Gossamer Bio San Diego, CA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Prostaglandin D2 receptor 2 (PTGDR2) | Target Info | Antagonist | [2] |
Reactome | Prostanoid ligand receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03683576) A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma. U.S.National Institutes of Health. | |||
REF 2 | Results of a Phase 2b Trial With GB001, a Prostaglandin D(2) Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 Aug;162(2):297-308. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.